At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. | Gilead Sciences’ sponsorship of a ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a ...

It holds more than 40% of the US market share. Gilead Sciences Inc. (NASDAQ:GILD) is now developing lenacapavir for twice-yearly HIV prevention with regulatory filings underway in the US and Europe.

Biotech bigwig Gilead Sciences, Inc. GILD is scheduled to report first-quarter 2025 results on April 24, after market close.